Into China three years or twice face the price of waist cut! How does Pfizer's pillar products break the siege?

"As a generic, the difference between price and imported products is less than 200 yuan, which is clearly not good enough."an arthritis patient in the groupAfter the 2019 National Health Care Negotiations, many patients in the country are using the fenyceic toabici tablets to announce price cuts into health care, and patients who originally bought generic drugs from Bangladesh are delighted after the national organization of health-care negotiationsat the same time, in the past less than a year, three domestic generic drugs were approved for the market, but relative to the original research drug into the price of health insurance, patients issued the above-mentioned sighand on July 6th, the generic drug, which is in the middle of the day, announced another price cut in Yunnan and Sichuantofatib, the world's first small molecule-targeted JAK kinase inhibitor for rheumatoid arthritis, was approved by the U.SFDA in November 2012 for the treatment of adult patients with moderate to severe rheumatoid arthritis, followed by the expansion of a variety of adaptations such as psoriasis arthritis, ulcerative colitis and other adaptations, tofatib is also Pfizer's fifth-largest product, with 2019 results showing global sales of $2.242 billion, up 26 percent from a year earlier, and a 7 percent increase in the first quarter of this yearin China, Tofatib was approved in 2017 and is currently only used to treat adult patients with rheumatoid arthritisNegotiate access to the Category B health insurance catalog in 2019Pfizer is expanding its domestic certification for plaque-like psoriasis, active psoriasis arthritis, and juvenile iexclusiveidarthritisas for the sales of Tofateb in China, Minnet data show that its 2019 public medical institutions end sales of 43.62 million yuan, up 423.02 percent year-on-year, approved for three years, the product is in a period of rapid growthit's worth saying that two years after China's approval, Tofateb negotiated a price cut into the health care catalog, at the same time, also in two years by the impact of generic drugs, more embarrassingly, Tofatib this year was included in the third batch of national collection, into China three years or face two price cutsTofatib has become a clear case of china's pharmaceutical market reform in recent yearsFor Pfizer, the still growing TOP5 product in China and around the world will face a stormy price cut and a rapid siege of genericsfirst,, in terms of price, Pfizer was priced at around 1990 yuan per bottle (5mg x 28), and two years later, in the 2019 health-care negotiations, Pfizer included the tofatib in the health care system by cutting prices Also negotiated during the same period are two rheumatoid arthritis biologics, Adamu monotonica and Inphyse Pfizer chose to keep it a secret as it negotiated the price of health care But at present, the major terminals have made price adjustments, patients in the hospital to buy the price is 980 yuan (there are also patients said 960 yuan), as to the medical insurance payment price is not yet accurate news Visible, in the health care negotiations, Thefatibu played a 5 percent discount and on July 6th, Zhengda Tianqing adjusted the price of its generic drugs in Yunnan and Sichuan from 780 yuan to 750 yuan, a small drop in prices It is precisely because of this relative to the original study of 75% discount price, triggered the first patient's sigh It is worth noting that before the health care negotiations, the price of Zhengda Qing was 1250 yuan, about 60% of the original research health-care negotiations directly reducethe price difference between primary research and generic drugs in patients' minds A patient in Beijing area said: Pfizer's Tofateb 960 yuan a box, a month to use two boxes of a total of 1960 yuan, through the medical insurance reimbursement after the price is lower, Beijing after the medical insurance reimbursement of the cost of individuals to pay less than 600 yuan per month, is the big day Qingtofatib 798 yuan a box, a month to use two boxes of a total of 1596 yuan, the same access to health insurance, but most of the hospitals do not have medicine in the eyes of patients, the original research and imitation of the price after reimbursement is not much difference, and zhengda sunny approval time is less than a year, coupled with the impact of the epidemic, the current hospital admission effect is not ideal (there may be regional differences) apparently, the generics have also suffered a wave of embarrassment after the health-care negotiations but in the Chinese market, where the external environment is changing dramatically, the current pattern may soon be broken, and companies will not sit back In 2020, Tofateb will face the "1-plus-three" market landscape and the baptism of volume procurement following the approval of the first counterfeit in September 2019, Qilu and Collum's generic drugs have also been approved, "1-3" market pattern has been formed, but the current price pattern will last less than a year Qilu's Tofatib was approved at the end of October 2019, Jiangsu, Ningxia, Hainan and other places of tender information show that the price of 880 yuan, between Zhengda Qing qing and Pfizer, about 10% after the original negotiations The generic version of Collum Pharmaceuticals was approved a week ago and there is no price information in the face of negotiations to reduce the price of the original research products, Zhengda Qing in addition to the hospital market price reduction, according to some patients, early this year, in Henan, Jilin and other places in the pharmacy also carried out drug-giving activities E drug manager on July 8 dialed a pharmacy in Zhengzhou City, according to the other side, the current generic drug gift activities are still in progress: "buy two give one, a total of 1572 yuan, and support health insurance payment." "Equivalent to the price of a bottle of 524 yuan, about the original research level of 50%, Zhengda Tianqing in the outside market once again opened the price difference in addition, the above three generic drugs are approved in four types of generic drugs, as if through consistency evaluation, which means that all three have received this year's third batch of national collection of tickets In addition, the domestic application / as if applied for the product consistency evaluation is also Yangzijiang, Chengdu Bete, stone medicine, such as More than ten enterprises 's patent for Tofatib was originally due to expire in 2020, but it was pulled into the war with generics early because of the success of the patent challenge In the current price pattern, according to the previous two harvest decline, the second half of this year, the more competitive Tofatibu may have another price cut For Pfizer, the TOP5 product in the stock, in China in the three years of approval facing two major heavy policies and generic drugs, ushered in a number of price cuts, will have a significant impact on its sales just down the health care bureau's negotiating table, the field ushered in generic / similar drug competition, followed by several domestic pharmaceutical companies with the same amount of procurement competition, such a scenario with the health care negotiations and the volume procurement process accelerated, encryption, will not only Pfizer need to face AstraZeneca's Gifitini and Tegrillo, and the new-key Azasin, among others, have experienced or are about to experience two big-weight policy killings before the publication of the third batch of national belt procurement varieties, there have been predictions in the industry that biosimilars will be included in the collection, and most of these varieties of the original research have experienced health insurance negotiations Although the final prediction scored, the possibility of biosimilars being included in the collection remains at present, there are only four approved biological similar drugs, but in two years, Adamu monotenofagain, belavbead monotometrean, qutodzumab, lituximatoritus and other large global varieties will usher in full competition in the country, and sales and degree of competition is also included in the importance of one of the important criteria for the purchase of the band In addition, some products in recent years into China's liver disease, diabetes and other fields also have similar risks Thus, future market access for pharmaceutical companies may need to seriously consider market strategies such as these two policy gates and pricing.